CAJ | 학술논문

氯吡格雷是一种新型噻吩吡啶类抗血小板药物，联合应用氯吡格雷及阿司匹林已经成为急性冠脉综合征及经皮冠状动脉介入支架术后患者的标准治疗方案。与氯吡格雷吸收和代谢通路相关的基因变异，使得患者对氯吡格雷的临床反应性存在显著的个体差异，部分患者出现氯吡格雷抵抗现象，增加临床不良事件的发生。确定相关基因变异对指导临床个体化用药实践意义重大。
록필격뢰시일충신형새분필정류항혈소판약물，연합응용록필격뢰급아사필림이경성위급성관맥종합정급경피관상동맥개입지가술후환자적표준치료방안。여록필격뢰흡수화대사통로상관적기인변이，사득환자대록필격뢰적림상반응성존재현저적개체차이，부분환자출현록필격뢰저항현상，증가림상불량사건적발생。학정상관기인변이대지도림상개체화용약실천의의중대。
Clopidogrel is a second-generation thienopyridine which prevents platelet aggregation. Dual antiplatelet therapy including clopidogrel and aspirin is regarded as standard medical care in patients suffering from acute coronary syndromes and in those undergoing percutaneous coronary intervention (PCI) with stent implantation. Data suggests that there is large interindividual variability in clopidogrel efficacy and a part of patients resist clopidogrel, resulting in cardiovascular complications. This article reviews the role of genetic polymorphisms on clopidogrel resistance in order to guide clinical individualized medication.